Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Increased risk of urinary incontinence with hormone therapy

Menopausal hormone therapy (MHT), consisting of oral estrogen plus progestin or estrogen alone, considered in the past as treatment for urinary incontinenc, was until recently, credited with many benefits well beyond the indications for symptomatic relief of hot flashes, night sweats, and vaginal dryness. One of the benefits of MHT was to improve the symptoms of urinary incontinence (UI), and it has often been prescribed to treat UI.

21 Feb 2005

Clinical trial planned for stem cell treatment for stress urinary incontinence

ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence.

24 Jan 2005

FDA approves Enablex for the treatment of overactive bladder

Novartis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Enablex® (darifenacin) extended-release tablets (7.5mg and 15mg) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.

22 Dec 2004

Researchers are successfully treating incontinent women with the patient's own muscle-derived stem cells

Austrian researchers are successfully treating incontinent women with the patient's own muscle-derived stem cells. The findings of the first clinical study of its kind were presented today at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2004

Urinary incontinence and abdominal pain are key symptoms of ovarian cancer

Results from an Olmsted Medical Center and Mayo Clinic study analyzing symptoms recorded in the medical records of ovarian cancer patients suggest ovarian cancer, long considered asymptomatic until late-stage cancer develops, does in fact have early symptoms, including urinary incontinence and abdominal pain.

18 Nov 2004

Urinary incontinence is passed down from mother to daughter

New research from the University of Bergen (UiB), Norway, shows that a woman who’s mother has urinary incontinence has a 30 percent greater chance for incontinence herself.

4 Nov 2004

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

The antidepressant Cymbalta (duloxetine HCl), a dual-reuptake inhibitor of serotonin and norepinephrine, 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression, according to 12-week data presented at the annual meeting of the American College of Rheumatology.

18 Oct 2004

Prostate cancer treatment leads to declines in sexual and urinary function

Treatment for prostate cancer leads to significant five-year declines in sexual and urinary function, according to a new study. However, general and other specific health-related quality of life factors, such as bowel function, are not affected.

27 Sep 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Yentreve available in Europe for treatment of stress urinary incontinence

Yentreve (duloxetine hydrochloride) is now available in certain European countries, giving women suffering from moderate to severe stress urinary incontinence (SUI) a pharmaceutical treatment option for the first time.

13 Sep 2004

Cymbalta approved for diabetic peripheral neuropathy pain

The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.

8 Sep 2004

Cymbalta, treatment for major depression hits the market

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company has announced.

26 Aug 2004

Cymbalta, a new treatment for major depression

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company have announced.

25 Aug 2004

Pfizer drug effectively treats overactive bladder symptoms

Women with mixed incontinence, a combination of overactive bladder and stress incontinence, reported a greater treatment benefit for overactive bladder symptoms from DETROL® LA (tolterodine tartrate extended release capsules) than placebo, according to new study results published in the August issue of Urology.

21 Aug 2004

Evidence of pelvic floor nerve injury after routine vaginal birth

Women with pelvic floor disorders suffer from urinary and fecal incontinence as well as prolapse of the bowel, bladder and reproductive organs. (Bowel prolapse occurs when the bowel slips out of place, and pushes up against the walls of the vagina, which may cause a great deal of discomfort.)

20 Aug 2004